Clinical Trial

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

Study acronym: PIONEER-PKD
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-01-26 -> 2027-05-22 2026-07-29
minor Completion pushed: 2027-01-26 -> 2027-05-22 2026-07-29
Trial Details
NCT Number NCT07228364
Lead Sponsor AstraZeneca
Conditions Autosomal Dominant Polycystic Kidney Disease
Enrollment 40 participants
Start Date 2025-11-10
Primary Completion 2027-05-22 (estimated)
Study Completion 2027-05-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-28